Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) of 19 to 26 kg/m2, inclusive 19 and 26. BMI = weight (kg)/\[height(m)\]2.~* Subjects are fully informed and voluntarily consent to participate in this study.~Exclusion Criteria:~* History of allergy or hypersensitivity.~* Presence of any acute or chronic medical condition within 3 months prior to investigational products administration, including but not limited to: hepatic, gastrointestinal, renal, hematologic (including coagulation), pulmonary, neurologic, respiratory, endocrine, or cardiovascular system abnormalities; psychiatrical disease including major psychiatric disorders (e.g., schizophrenia, bipolar disorder); acute infection; or other conditions that would interfere with the absorption, distribution, metabolism, or excretion of drugs.~* During the screening period, abnormal and clinically significant of physical examination, vital signs, laboratory examination, etc.~* A positive result in hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test.~* Lost blood or donated more than 400 mL of blood within 3 months prior to the screening.~* Participation in a clinical drug study 30 days prior to present study.~* Use of any other drugs within 2 weeks prior to the screening.~* Subjects planning to give birth or donate sperm during the study or within 3 months after the study.~* The partner of the subject is unwilling to take effective contraceptive measures.~* Other unfavorable factors diagnosed by investigators.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ABCD (Type: EXPERIMENTAL): Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).